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Cetuximab and panitumumab efficacy in metastatic colorectal cancer (mCRC) may be influenced by EGFR gene status and/or
deregulation of its downstream signalling proteins detected in primary tumour. However, metastasis might have different molecular
patterns with respect to primary tumour, possibly affecting the prediction of EGFR-targeted therapy efficacy. We analysed primary
tumour and metastasis in 38 mCRC patients. Twelve cases were cetuximab/panitumumab treated. EGFR gene status and protein
expression were investigated through fluorescent in situ hybridisation and immunohistochemistry (IHC), K-Ras/BRAF mutations by
sequencing and PTEN expression by IHC. We observed EGFR gene deregulation in 25 out of 36 primary tumours and 29 out of 36
metastases, K-Ras mutations in 16 out of 37 cancers and in 15 out of 37 metastases, BRAF mutations in 2 out of 36 cancers and 2 out
of 36 metastases and PTEN loss in 8 out of 38 cancers and 12 out of 38 metastases. For the first time in literature, we show that
primary colorectal cancer and paired metastasis may exhibit difference with respect to EGFR pathway deregulation mechanisms
possibly implying a different response to cetuximab or panitumumab treatment. The investigation of treated patients confirms this
hypothesis. We therefore suggest that the analysis of metastatic lesion should be considered in patient management as well as in
designing future clinical trials aimed to investigate the effect of anti-EGFR monoclonal antibodies in the treatment of mCRC.
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Epidermal growth factor receptor (EGFR) is a member of
the transmembrane tyrosine kinase receptor family ErbB, involved
in controlling cell growth, differentiation and proliferation by
triggering both the Ras–RAF–MAP kinase pathway and the
PI3K–PTEN–Akt pathway (Ciardiello and Tortora, 2008). Epi-
dermal growth factor receptor constitutive activation leads to
malignant transformation, angiogenesis and metastatic dissemina-
tion. Owing to its relevance in cancer development, EGFR
represents a natural molecular target for a new class of anticancer
drugs. In colorectal cancer, where EGFR is overexpressed in a
consistent number of cases, cetuximab and panitumumab, two
monoclonal antibodies (MoAbs) that recognise the extracellular
domain of the receptor leading to its inactivation, have entered in
clinical practice for the treatment of metastatic disease (Ciardiello
and Tortora, 2008). Both drugs, however, are effective only in
approximately 10% of metastatic colorectal cancer (mCRC)
patients (Ciardiello and Tortora, 2008), underscoring therefore
the need of simple tests able to predict a response to these agents.
To date, several studies demonstrated that EGFR protein
expression detected by immunohistochemistry (IHC) in cancer
specimens is insufficient to determine response to cetuximab
therapy (reported in Chung et al, 2005). By contrast, EGFR gene
copy number gain (CNG, due to either polysomy or gene
amplification), evaluated by fluorescent in situ hybridisation
(FISH), seems to be a better predictive marker for anti-EGFR
MoAb sensitivity (Lie `vre et al, 2005; Moroni et al, 2005; Cappuzzo
et al, 2007; Frattini et al, 2007; Sartore-Bianchi et al, 2007;
Personeni et al, 2008), whereas the presence of K-Ras mutations
and/or loss of PTEN protein expression by IHC predicts resistance
to these drugs (Lie `vre et al, 2005; Moroni et al, 2005; Benvenuti
et al, 2007; Cappuzzo et al, 2007; Di Fiore et al, 2007; Frattini et al,
2007; Khambata-Ford et al, 2007; Sartore-Bianchi et al, 2007;
De Roock et al, 2008; Lie `vre et al, 2008).
All these data have been obtained by analysing clinical response
in mCRC patients with regard to molecular features detected in
primary tumour. It is possible, however, that primary tumour and
paired metastatic lesions might be different at the molecular
marker expression or gene status levels and that these differences
may affect the clinical significance of a predictive test. In this
contest, it is noteworthy that the few previously published studies
on this issue focused almost exclusively on the rather unreliable
evaluation of EGFR expression by IHC (McKay et al, 2002; Ooi et al,
2004; Scartozzi et al, 2004; Bralet et al, 2005; Italiano et al, 2005;
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sBibeau et al, 2006; Cappuzzo et al, 2007). The aim of this study
is to analyse molecular alterations predictive for anti-EGFR
therapies response, such as EGFR gene status, K-Ras and BRAF
mutations, and PTEN protein expression, in primary tumour
and synchronous or metachronous metastasis. In patients treated
with MoAbs against EGFR, the molecular and clinical data were
matched.
PATIENTS AND METHODS
Patient population and treatment regimens
The analysis was conducted in 38 patients who underwent primary
surgery for colorectal cancer presenting with synchronous or
developing metachronous metastasis and who were identified from
the database of the local cancer registry (www.ti.ch/tumori). Tissue
specimens were available for both primary tumour and metastasis,
and they were evaluated at the local institute of pathology
(www.ti.ch/icp) after fixation in 4% neutral buffered formalin.
All tumours were adenocarcinomas. Twelve patients were treated
with cetuximab- or panitumumab-based regimens at the Oncology
Institute of Southern Switzerland. With the exception of one
patient who received cetuximab as a frontline therapy, the others
had failed at least one prior chemotherapy regimen based on
irinotecan. For the last patients, the MoAbs were administered in
combination with irinotecan given at the same dose and schedule
as previously used. Treatment was continued until progressive
disease (PD) or toxicity occurred, according to the standard
criteria (Therasse et al, 2000) or to specific trial guidelines.
Patients evaluated in this study were selected based on evidence
that treatment outcome could be attributable only to administra-
tion of either panitumumab or cetuximab.
Clinical evaluation and response criteria
The response was assessed every 6 weeks with radiological
examination (computerised tomodensitometry or magnetic reso-
nance imaging). The Response Evaluation Criteria in Solid Tumors
were adopted for evaluation and classified as partial response (PR),
as stable disease (SD) or PD. Patients with SD or PD were defined
as non-responders (NRs) (Therasse et al, 2000). Response to
therapy was also evaluated retrospectively by independent
radiologists.
Molecular analyses
All formalin-fixed paraffin-embedded tumour blocks were reviewed
for quality and tumour content, and a single representative tumour
block from each case, containing at least 70% of neoplastic cells,
was selected for immunohistochemical, cytogenetic and molecular
analyses. Tumour macrodissection was performed in tumour
blocks containing less than 70% of neoplastic cells (to reduce the
presence of non-neoplastic tissues). Genomic DNA was extracted
using the QIAamp Mini kit (Qiagen, Chatsworth, CA, USA)
according to the manufacturer’s instructions.
Immunohistochemistry: Epidermal growth factor receptor pro-
tein expression was evaluated on 3mm thick tissue sections using
the EGFR pharmDx assay (Dako Cytomation, Carpinteria, CA,
USA) according to the manufacturer’s instructions, as reported
earlier (Frattini et al, 2007). Tissue samples were considered EGFR
positive if at least 1% of malignant cells were stained for EGFR. As
external controls, we used those included in the kit.
PTEN protein expression status was performed according to
the literature (Saal et al, 2005; Frattini et al, 2007). PTEN
protein expression was detected mainly at the cytoplasmic level,
although occasional nuclear positivity was present. We considered
PTEN negative those specimens showing a strong reduction or
absence of immunostaining in at least 50% of cells, as compared
with either the internal (normal colon mucosa) or external (normal
endometrium) control.
All immunohistochemical analyses were performed by two
independent observers (SC and LM) giving superimposable results.
The evaluation was performed without knowledge of clinical
evaluation of the results of other analyses.
Fluorescent in situ hybridisation: EGFR gene status evaluation
was performed on 3mm thick tissue sections that were treated
using Paraffin Pretreatment kit II (Vysis, Downer’s Grove, IL,
USA) according to the manufacturer’s instructions. Dual-colour
FISH assay was performed using LSI EGFR/CEP7 probes (Vysis),
as mentioned earlier (Frattini et al, 2007). The LSI EGFR probe is
labelled in SpectrumOrange and covers an approximately 300kb
region that contains the entire EGFR gene at 7p12. The CEP7
probe, labelled in SpectrumGreen, hybridises to the a-satellite
DNA located at the centromere of chromosome 7 (7p11.1–q11.1).
To overcome the problem of tissue heterogeneity, we evaluated 10
different tumour areas and at least 10 representative nuclei from
each area. Overall, a total of 100 cells for each patient were scored.
For cases in which only a biopsy was available, we evaluated all
the analysable nuclei. Cases showing two chromosome 7 (Chr7) in
more than 50% of cells were classified as disomic. Tumour samples
with an aberrant number of Chr7, defined as more than four in at
least 50% of cells, were classified as markedly polysomic.
Specimens with a ratio of more than 2 between EGFR gene and
Chr7 centromere signals in at least 10% of cells were classified as
carrying EGFR gene amplification.
The EGFR gene status evaluation was performed by two
independent observers (FM and VM) giving superimposable
results. The evaluation was performed without the knowledge of
clinical evaluation of the results of other analyses.
K-Ras and BRAF mutational status: We searched for K-Ras point
mutations in codons 12 and 13, two hotspots that cumulatively
include more than 95% of mutations in this gene, as already
reported (Frattini et al, 2007). BRAF mutations were investigated
in exon 15, in which more than 95% of BRAF point mutations
occur, as reported earlier (Frattini et al, 2004). All samples were
subjected to automated sequencing by ABI PRISM 3100 (Applied
Biosystems, Foster City, CA, USA) and analysed with Chromas
software (http://www.technelysium.com.au/chromas.html). Each
sequence reaction was performed at least twice, starting from
independent PCRs. In each case, the detected mutation was
confirmed in the sequence as sense and antisense strands.
Statistical analyses
The association between primary tumours and related metastatic
sites for EGFR gene status, BRAF and K-Ras mutational status,
and PTEN protein expression was evaluated by means of the
Cohen’s k-test, appropriate for the assessment of the concordance
between two categorical measurements of the same individual.
A moderate and good agreement was defined as the coefficient
was 0.41pkp0.60 and 0.61pkp0.80, respectively (Landis and
Koch, 1977). All statistical tests were two sided. Significance
levels were set at Pp0.05. All statistical analyses were carried
out using the SAS System V 9.1 Software (SAS Institute Inc., Cary,
NC, USA).
RESULTS
Patient characteristics
Patient characteristics are summarised in Table 1. Thirty-eight
patients, 24 men (63%) and 14 women (37%), were included. The
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smedian age at the time of diagnosis was 67 years (range from 48 to
94 years). Twenty-nine patients had a colon cancer (76%,
14 patients in the right and 15 in the left/sigmoid colon) and
nine carried a rectal cancer (24%). All, but one, patients were
stage pT3/T4. Twelve carcinomas (32%) were classified as
poorly differentiated and 26 (68%) as well or moderately
differentiated.
Samples from metastatic sites (n¼53) included 15 lymph nodes
and 38 visceral metastases located in the liver (28 out of 38¼74%),
lung (3 out of 38¼8%), omentum (3 out of 38¼8%), peritoneum
(2 out of 38¼5%) and brain (2 out of 38¼5%). In 19 patients,
distant metastasis was confined to one site, whereas 19 patients
had multiple metastases. Metastases were synchronous in 25 cases
and metachronous in the remaining 13 patients.
Twelve patients were treated with MoAbs against EGFR and
clinical follow-up data were available in all cases. Cetuximab or
panitumumab was administered in combination with chemo-
therapy as upfront therapy in one case, as second line in four cases,
as third line in four cases and as fourth line in three cases. Two
patients (17%) achieved PR after cetuximab-based therapy
(Table 2).
EGFR protein expression
All tumour samples showed a positive EGFR expression as
detected by IHC. Overall, the same pattern of EGFR protein
expression between primary tumour and related metastasis, either
at distant sites or in lymph nodes, was observed in all cases (k¼1,
Po0.0001) (Table 2).
EGFR gene status
Two cases were excluded due to inadequate fixation of tissue
sample (nos. 8 and 24, Table 2). Of the 36 remaining cases, Chr7
loss was observed in 1 (3%) primary tumour, Chr7 disomy in 10
(28%) cases, Chr7 polysomy in 17 (47%) and EGFR gene
amplification in 8 (22%) cases (Table 2). In metastatic sites,
EGFR gene status was classified as Chr7 loss in 1 (3%) case, Chr7
disomy in 6 (17%), Chr7 polysomy in 21 (58%) and EGFR gene
amplification in 8 (22%) cases (Table 2). The same pattern between
primary tumour and related distant metastasis was observed in
24 out of 36 (67%) patients (Table 2). Among those who exhibited
differences between cancer and metastatic specimens, a trend in
favour of deregulation was observed in eight cases (from Chr7
disomy to polysomy in six cases and from Chr7 polysomy to
gene amplification in two cases), whereas four patients showed
gene amplification or Chr7 polysomy in primary cancer and Chr7
polysomy or disomy, respectively, in related distant metastatic
sites (Figure 1). If we consider the cases showing either Chr7
polysomy or EGFR gene amplification as a single group, we
observed differences in eight patients (8 out of 36¼22%), namely
two cases with EGFR deregulation limited to primary tumour and
six cases to the metastasis (k¼0.49, P¼0.0002), thus revealing a
moderate level of agreement between the two sites. In seven cases
with a different EGFR gene status pattern between primary tumour
and distant metastasis and for which a lymph node metastasis was
available, the EGFR gene status in the lymph node lesion was
similar to that in primary tumour in five cases and to distant
metastasis in two cases (Table 2).
K-Ras mutational status
One case was excluded due to the bad quality of DNA (no. 24,
Table 2). Sixteen primary tumours (43%) carried a K-Ras point
mutation, of which 13 occurred at codon 12 and 3 at codon 13.
Mutations at codon 12 predominantly involved the second base,
with prevalence of the GcT (GGT-GcT, Gly-Ala, G12A) and GaT
(GGT-GaT, Gly-Asp, G12D) changes, in six and four cases,
respectively, whereas one patient showed the 12GtT codon (GGT-
GtT, Gly-Val, G12V). Only one patient carried a K-Ras mutation
involving the first base of codon 12, leading to the 12aGT change
(GGT-aGT, Gly-Ser, G12S). The mutations found at codon 13
corresponded to the classical transition G-A in the second base of
the codon (GGC-GaC, Gly-Asp, G13D) (Table 2).
At metastatic lesions, we observed a K-Ras mutation in 15
patients. Overall, the same mutational pattern between primary
tumour and related metastasis was observed in 34 out of 37 (92%)
patients (Table 2). Among those who exhibited differences between
cancer and metastatic specimens, two patients had a point mutation
limited to primary tumour (one case with a 12tGT change and one
with a 13GaC change) and one case to the metastasis (GGT-tGT,
Gly-Cys, G12C (k¼0.83, Po0.0001)) (Figure 2).
Lymph node metastasis had a K-Ras mutational pattern
corresponding to that observed in primary tumours.
BRAF mutational status
Two cases were excluded due to the bad quality of DNA (nos. 8 and
24, Table 2). The classical BRAF point mutation occurring at codon
600, leading to the amino-acid change V600E, was observed in two
Table 1 Clinicopathological characteristics
Patient characteristics (N¼38) Number of cases Percentage (%)
Age
p60 years 9 24
460 years 29 76
Gender
Male 24 63
Female 14 37
Tumour location
Proximal colon 14 37
Distal colon 15 39
Rectum 9 24
Grade
Well/moderate 26 68
Poor 12 32
TNM classification
T2 1 3
T3 21 55
T4 13 34
Unknown 3 8
Metastasis site analysed
Peritoneal carcinomatosis 2 5
Liver 28 74
Lung 3 8
Omenthum 3 8
Brain 2 5
Number of metastasis
Single 19 50
Multiple 19 50
Metastatic lesions
Synchronous 25 66
Metachronous 13 34
Primary tumour
Biopsy 3 8
Resection 35 92
Metastatic lesion
Biopsy 15 39
Resection 23 61
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metastatic lesions (Table 2). Overall, the same mutational pattern
between primary tumour and related metastasis, either at distant
sites or in lymph nodes, was observed in all cases (k¼1, Po0.0001)
(Table 2). In the two patients carrying a BRAF mutation we did not
detect any point mutation in the K-Ras gene (Table 2).
PTEN protein expression
PTEN protein expression could be evaluated in all tissue samples
by IHC. Normal PTEN expression was documented in 30 out of 38
(79%) primary tumour specimens, whereas a loss of PTEN was
found in 8 (21%) cases. In distant metastatic lesions, 26 (68%)
cases showed a normal PTEN expression, whereas 12 (32%) cases
were classified as PTEN negative. Overall, the same PTEN protein
expression pattern between primary tumour and related metastasis
was observed in 34 cases (89%, Figure 3). Four cases with a normal
expression of PTEN in primary tumour showed a complete
loss of expression (nos. 8 and 36, Table 2) or a dramatical reduc-
tion of protein expression in related distant metastatic sites (nos.
28 and 31 (k¼0.73, Po0.0001), Table 2, Figure 3). Lymph node
metastasis had a PTEN immunophenotype similar to that observed
in distant metastatic specimens.
Clinical response and relationship with molecular profile
Twelve patients were treated with MoAbs against EGFR and
clinical data were collected. Seven patients showed a molecular
profile in the primary tumour superimposable with that observed
in visceral metastases (Table 2). Of these seven patients, two
experienced a PR to the drug and were characterised by CNG
in EGFR gene status and absence of any alteration in the
EGFR downstream pathways. Five patients were NRs and were
characterised by the absence of either EGFR CNG or EGFR CNG
plus an alteration occurring in one member of EGFR downstream
pathways (K-Ras or PTEN) (Table 2).
In five patients, all NRs, the molecular profile in primary
tumour and related distant metastatic sites was discordant.
Out of these, four patients showed differences in either EGFR
gene status or PTEN protein expression (two cases each, nos.
27 and 29, nos. 28 and 31, respectively), but carried an
additional mutation in the K-Ras or BRAF gene both in primary
tumour and metastasis. The fifth patient (no. 36) showed
loss of PTEN expression limited to the metastasis but with
EGFR CNG, and the absence of any additional alteration in
downstream pathways both in primary tumour and metastasis
(Table 2).
Table 2 Immunohistochemical, cytogenetic and molecular data
EGFR IHC EGFR FISH K-Ras BRAF PTEN IHC
Case no. T LN M T LN M T LN M T LN M T LN M Clinical response
1 + + +P A AW TW TW TW TW TW T+ + +  
2 + NA + P NA D G12A NA G12A WT NA WT   NA   
3 + + + P NV P WT WT G12C WT WT WT + + +  
4 + NA + A NA P G12D NA G12D WT NA WT   NA   
5 + + + P P P G12A G12A G12A WT WT WT      
6 + + +DD PW TW TW TW TW TW T     
7 + NA + P NA P G12C NA WT WT NA WT   NA   
8 + NA + NV NA NV WT NA WT NV NA NV + NA   
9 + + + P P P G13D G13D G13D WT WT WT + + +  
10 + NA + A NA A WT NA WT WT NA WT + NA +  
11 + + + A A P WT WT WT WT WT WT + + +  
12 + NA + A NA A WT NA WT WT NA WT + NA +  
13 + NA + A NA A WT NA WT WT NA WT + NA +  
14 + NA + P NA P WT NA WT WT NA WT + NA +  
15 + NA + D NA D WT NA WT WT NA WT + NA +  
16 + NA + P NA P G12D NA G12D WT NA WT + NA +  
17 + NA + P NA P G13D NA WT WT NA WT + NA +  
18 + NA + P NA P G13D NA G13D WT NA WT   NA   
19 + NA + L NA L WT NA WT WT NA WT + NA +  
20 + + + P P P G12V G12V G12V WT WT WT + + +  
21 + NA + D NA P WT NA WT WT NA WT + NA +  
22 + + + P P D WT WT WT WT WT WT + + +  
23 + + + D D P G12A G12A G12A WT WT WT + + +  
24 + NA + NV NA NV NV NA NV NV NA NV + NA +  
25 + + + D D D WT WT WT V600E V600E V600E + + + NR
26 + + + D D D G12D G12D G12D WT WT WT + + +  
27 + + + D P P G12A G12A G12A WT WT WT     NR
28 + + + P NV A G12A G12A G12A WT WT WT +    NR
29 + + + D D P G12D G12D G12D WT WT WT + + + NR
30 + NA + A NA A WT NA WT WT NA WT + NA + PR
31 + + + P P P WT WT WT V600E V600E V600E +    NR
32 + NA + D NA D WT NA WT WT NA WT + NA + NR
33 + NA + A NA A WT NA WT WT NA WT + NA + PR
34 + NA + P NA P G12S NA G12S WT NA WT + NA + NR
35 + NA + P NA P G12A NA G12A WT NA WT + NA + NR
36 + NA + P NA P WT NA WT WT NA WT + NA   NR
37 + NA + D NA P WT NA WT WT NA WT + NA +  
38 + NA + A NA A WT NA WT WT NA WT   NA   NR
Abbreviations: A¼EGFR gene amplification; D¼chromosome 7 disomy; L¼chromosome 7 loss; LN¼lymph node metastases; M¼distant metastatic sites; NA¼not available;
NR¼non-responsive; NV¼not evaluable; PR¼partially responsive; P¼chromosome 7 polisomy; T¼primary tumour; WT¼wild-type; ‘+’¼positive expression;
‘ ’¼negative expression.
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sDISCUSSION
Epidermal growth factor receptor-targeted molecular therapies
have acquired high relevance in the treatment of mCRC. However,
the administration of anti-EGFR MoAbs (cetuximab and panitu-
mumab) prolongs the survival rate of only a subset of mCRC
patients (Ciardiello and Tortora, 2008). The identification of
clinical and/or pathological features, or of molecular alterations
able to predict sensitivity or resistance to anti-EGFR therapies,
is therefore urgently needed. Currently, the prerequisites for
cetuximab or panitumumab administration are represented by
the EGFR immunohistochemical overexpression and, limited to
panitumumab, by the absence of K-Ras mutations, according to
FDA and EMEA guidelines (www.fda.org; www.emea.europa.eu).
A
Primary Tumour Metastasis
B
CD
A G C T GG T GGC G T A GG
A G C T GG T GGC G T A GG A G C T GG T GGC G T A GG
A G C T GG T GGC G T A GG
Figure 2 Representative examples of the K-Ras mutation status differences in primary tumour and related metastasis in mCRC. Wild-type K-Ras gene in
the primary tumour (A) and G12C mutation in the paired metastasis (patient no. 3) (B). K-Ras G12C mutation in primary tumour (C) and K-Ras wild-type
sequence in paired metastasis (patient no. 7) (D).
A
C
Primary tumour Metastasis
B
D
Figure 1 Representative examples of EGFR gene status differences in primary tumour and related metastasis in mCRC. Chr7 disomy in the primary
tumour (A) and Chr7 polysomy in the paired metastasis (patient no. 6) (B); Chr7 polysomy in the primary tumour (C) and Chr7 disomy in the paired
metastasis (patient no. 2) (D).
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sRecent publications have clearly shown that the EGFR gene status
and its downstream protein alterations (K-Ras and PTEN) may
give additional information for a more accurate evaluation of anti-
EGFR treatment response (Lie `vre et al, 2005; Moroni et al, 2005;
Benvenuti et al, 2007; Cappuzzo et al, 2007; Di Fiore et al, 2007;
Frattini et al, 2007; Khambata-Ford et al, 2007; Sartore-Bianchi
et al, 2007; De Roock et al, 2008; Lie `vre et al, 2008). However, even
the evaluation of these additional molecular markers is not able to
fully predict EGFR-targeted drug response. This fact could be
explained by three putative mechanisms. (i) The use of inappro-
priate methodologies for the evaluation of a specific molecular
marker. For instance, it has been demonstrated that neither EGFR
protein expression evaluation by IHC nor EGFR mRNA expression
by RT–PCR represents the gold standard method for the
assessment of EGFR deregulation (Atkins et al, 2004; Langner
et al, 2004; Vallbo ¨hmer et al, 2005; Kersting et al, 2006), whereas
recent data suggest that EGFR gene status represents a better
predictive marker of anti-EGFR therapy sensitivity (Lie `vre et al,
2005; Moroni et al, 2005; Cappuzzo et al, 2007; Frattini et al, 2007;
Sartore-Bianchi et al, 2007). (ii) The involvement of other not yet
investigated genes. In this context, BRAF may represent a novel
predictive marker for anti-EGFR drug response (Benvenuti et al,
2007). (iii) the existence of different molecular patterns between
primary tumour and paired metastatic lesion as predictive
markers, so far, have been mostly evaluated in primary tumours
disregarding alterations at metastatic sites. To shed light into this
latter issue, earlier studies investigating primary tumours and
paired metastases by IHC revealed different patterns of
EGFR expression (McKay et al, 2002; Ooi et al, 2004; Scartozzi
et al, 2004; Bralet et al, 2005; Italiano et al, 2005; Bibeau et al, 2006;
Cappuzzo et al, 2007). Our data show that all primary tumours and
metastases were positive, although they showed different staining
intensities (data not shown).
The concept that primary tumour and distant metastasis may
indeed show different molecular patterns is supported by the
assessment of EGFR gene status by FISH. In our series, 12 cases
(33%) showed a discordant pattern. We found eight cases with a
trend in favour of EGFR gene deregulation from primary tumour
to metastasis and four cases with the opposite trend. These data
reflect those obtained by Italiano et al (2006) in non-small-cell
lung cancers. Several recent studies have demonstrated that
patients showing EGFR gene deregulation defined either by Chr7
polysomy or EGFR gene amplification (cumulatively named CNG)
could benefit from cetuximab treatment (Lie `vre et al, 2005; Moroni
et al, 2005; Cappuzzo et al, 2007; Frattini et al, 2007; Sartore-
Bianchi et al, 2007). Two groups of patients are therefore of
particular interest: patients with Chr7 disomy in primary tumour
and EGFR gene CNG in paired metastatic lesions, and patients with
A
Primary Tumour Metastasis
B
D C
F E
Figure 3 Representative examples of PTEN expression in primary tumour and related metastasis in mCRC. Equal PTEN immunohistochemical pattern
between primary tumour (A and C) and paired metastasis (B and D): PTEN-positive expression (A and B) and PTEN-negative expression (C and D).
Normal PTEN expression in the primary tumour (E) and reduction of PTEN immunodecoration in the metastatic lesion (F).
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sthe opposite pattern. The first group should not be addressed to
anti-EGFR MoAb treatments based on the sole primary tumour
evaluation, but eventually, it may benefit from these targeted
therapies because of the presence of EGFR gene CNG in metastatic
sites. The opposite may be valid for the second group of patients.
Our results demonstrate only a moderate correlation between
EGFR gene status in primary tumours and in corresponding
metastatic sites (k¼0.49, P¼0.0002), and suggest that in patients
with mCRC, EGFR evaluation by FISH performed only in primary
tumour may not be accurate enough to select candidates for a
targeted therapy. The heterogeneity of EGFR gene status in
neoplastic tissues obtained at different sites from the same patient
is confirmed by our findings in lymph node metastasis. In fact, in
patients with differences between primary tumour and related
distant metastasis, the EGFR gene status pattern observed in lymph
nodes was superimposable to primary tumours in six cases and to
distant metastasis in two cases. Our data are in contrast with those
of Cappuzzo et al (2007), who found that in 21 out of 22 cases the
FISH pattern of EGFR gene status in primary tumour and distant
metastatic sites is similar. This difference may be explained by
environmental factors or by FISH technique and evaluation
criteria. With respect to the latter point, it should be mentioned
that a general consensus for EGFR gene status evaluation by FISH
is currently lacking (Martin et al, 2008).
We extended the comparison between primary tumours and
metastatic sites to the analysis of molecular markers belonging to
EGFR downstream cascade, which have been previously identified
as potentially predictive for anti-EGFR MoAb efficacy.
The analysis of primary tumours revealed K-Ras mutations in
43% of cases, BRAF mutations in 6% of cases and PTEN loss of
expression in 21% of cases, in agreement with the earlier data
concerning sporadic colorectal cancers (Rajagopalan et al, 2002;
Frattini et al, 2005, 2007). We found a concordant pattern between
primary tumours and related distant metastatic sites in 34 out of
37 cases for K-Ras, in all cases for BRAF and in 34 out of 38 cases
for PTEN. These data show a good agreement between primary
tumours and related metastasis for the deregulation of EGFR
downstream members, in line with results available in the
literature for K-Ras and BRAF (Artale et al, 2008; Etienne-
Grimaldi et al, 2008). However, it is important to underscore that
the differences between the two sites may be clinically relevant for
a given patient. In fact, patients without K-Ras or BRAF gene
mutation, or with normal PTEN protein expression at primary
tumour level, may become resistant if their metastases show
alterations of these gene or proteins. By contrast, patients
potentially resistant to the treatment may benefit from MoAb
administration due to the absence of any alterations at metastatic
level. The fact that primary tumour and related metastasis could be
different in terms of gene mutations is confirmed by K-Ras
analysis in non-small-cell lung cancer (Kalikaki et al, 2008).
The clinical data concerning patients treated with EGFR-
targeted therapies are in line with these hypotheses. Indeed, one
patient did not respond to MoAbs by virtue of the absence of
PTEN expression limited to the metastatic lesion in a context of a
molecular profile proficient to MoAb response (EGFR CNG and no
additional alterations in EGFR downstream pathways in both
primary tumour and metastasis). In the other four patients
showing discordant molecular profiles between primary tumour
and metastasis and for whom clinical data were available, the
additional presence of either K-Ras or BRAF mutations at both
sites predicted resistance to therapy.
It is important to highlight that we analysed mainly resection
specimens (in 35 out of 38 primary tumours and in 23 out of 38
metastases), so that a discordant molecular pattern between
primary tumour and paired metastasis due to a sample effect,
although it cannot be excluded, is unlikely. Thus, the observed
differences between primary tumour and metastasis may be
explained by a trend in favour of gene or protein expression
deregulation when the alteration is acquired by metastatic cells,
whereas by a clone, present in a subgroup of primary tumour cells
and characterised by an EGFR-independent metastatic phenotype,
when the alteration is limited to primary tumour cells.
Finally, with respect to K-Ras, several additional issues are
worthy to be discussed. First, we confirm that K-Ras and BRAF
mutations are mutually exclusive (Rajagopalan et al, 2002).
Second, besides the expected occurrence of G12D mutation
(Frattini et al, 2007), we observed an unusual high frequency of
G12A mutations, suggesting that this type of K-Ras alteration may
confer a higher aggressive phenotype. Conversely, we found only
one case with the G12V change, thus reinforcing the knowledge
that this type of mutation may correlate with an indolent clinical
course (Finkelstein et al, 1993; Frattini et al, 2007). However, as
other studies showed discordant data (Andreyev et al, 2001),
additional studies on this issue are clearly warranted.
To our knowledge, this is the first study concerning the analysis
of EGFR protein expression and gene status, K-Ras and BRAF
mutations, and PTEN protein expression in primary tumours as
well as in lymph node and distant metastasis in the same cohort of
mCRC patients. Our data, demonstrating different deregulation
mechanisms of the EGFR pathways between primary tumours and
related metastasis, deserve confirmation in larger and prospective
studies. Nevertheless, the results may represent an important issue
in the clinical practice and should be taken into account in
designing future clinical trials based on anti-EGFR therapies.
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